Electrocore, Inc. (ECOR) Stock Price & Analysis
Electrocore, Inc. (ECOR) fell 1.24% to USD 9.52 as of June 10, 2026 at 09:04 UTC, according to Nexqual real-time market data.
ECOR last closed at USD 9.64; the session ranged USD 8.7–10 on volume of 118,394 shares. Market capitalization is $78.98M, with a 52-week range of USD 4.16–10.37 (NCM). Source: Nexqual, June 10, 2026 at 09:04 UTC.
Key Statistics (as of June 10, 2026 at 09:04 UTC)
| Price | USD 9.52 |
|---|---|
| Change | ▼ 1.24% (down) |
| Previous Close | USD 9.64 |
| Open | USD 9.64 |
| Day Range | USD 8.7 – 10 |
| 52-Week Range | USD 4.16 – 10.37 |
| Volume | 118,394 shares |
| Market Cap | $78.98M |
| Exchange | NCM |
Technical Analysis (ECOR)
Nexqual's technical model rates ECOR "BUY" based on 5 bullish and 1 bearish signals across 123 daily candles, as of June 10, 2026 at 09:04 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 63.74 (neutral) |
| vs SMA50 | Above (USD 7) |
| MACD | 0.87 (positive) |
Analyst Ratings (ECOR)
Wall Street analysts rate ECOR "None" based on 5 analysts, with a mean price target of USD 19.17 (range USD 12–26), per Nexqual as of June 10, 2026 at 09:04 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 19.17 |
| High Target | USD 26 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (ECOR)
| Next Earnings Date | 2026-08-05 |
|---|---|
| Revenue Estimate | $9.65M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.59 vs est -0.61 ▲ beat |
| 2025-12-31 | USD -0.34 vs est -0.39 ▲ beat |
| 2025-09-30 | USD -0.4 vs est -0.4 ▲ beat |
| 2025-06-30 | USD -0.44 vs est -0.33 ▼ miss |
Source: Nexqual, June 10, 2026 at 09:04 UTC.
Financials & Fundamentals (ECOR)
| Total Revenue | $34.90M |
|---|---|
| Revenue Growth (YoY) | +42.60% |
| Gross Margin | +87.25% |
| Operating Margin | -55.47% |
| Profit Margin | -44.08% |
| Current Ratio | 1.02 |
| Total Cash | $8.83M |
| Total Debt | $9.48M |
| Free Cash Flow | $-869,750 |
Source: Nexqual, June 10, 2026 at 09:04 UTC.
Financial Health Score (ECOR)
Nexqual rates Electrocore, Inc.'s overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 09:04 UTC.
| Growth | Strong — Revenue +27% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Mixed — $9M cash vs $9M debt |
| Cash Flow | Weak — FCF negative: -$870K, burning cash |
| Efficiency | Mixed — No data |
Ownership (ECOR)
| Insider Ownership | +37.19% |
|---|---|
| Institutional Ownership | +9.18% |
| Shares Outstanding | 8.30M |
| Float | 5.17M |
| Short % of Float | +3.57% |
Source: Nexqual, June 10, 2026 at 09:04 UTC.
Leadership (ECOR)
Electrocore, Inc. is led by Thomas J. Errico (age 72), Founder & Independent Chairman, per Nexqual as of June 10, 2026 at 09:04 UTC.
| Founder & Independent Chairman | Thomas J. Errico (age 72) |
|---|---|
| CFO & Interim President | Joshua S. Lev (age 40) |
| Chief Operating Officer | Michael Fox |
| Vice President of Sales & New Market Development | Mitch Deshon |
Major Backers & Investors (ECOR)
Notable institutional backers of Electrocore, Inc. include Balyasny Asset Management LP, Fidelity, Jaffetilchin Investment Partners, LLC, according to Nexqual as of June 10, 2026 at 09:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Balyasny Asset Management LP | 1.4% |
| Fidelity | 0.79% |
| Jaffetilchin Investment Partners, LLC | 0.7% |
| Wealthspire Advisors, LLC | 0.57% |
| International Assets Investment Management, LLC | 0.56% |
| Renaissance Technologies | 0.54% |
| HighTower Advisors, LLC | 0.43% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 5.35% |
| Geode Capital | 0.94% |
| BlackRock | 0.48% |
Source: Nexqual, June 10, 2026 at 09:04 UTC.
From Electrocore, Inc.'s Latest SEC 10-K Filing (filed 2026-03-19)
Key Strengths & Strategy (as disclosed to the SEC)
- electroCore, Inc., a bioelectronic technology medicine and general wellness company, provides non-invasive vagus nerve stimulation (nVNS) technology platform in the United States, the United Kingdom, and internationally.
- The company develops gammaCore, a prescription only handheld device intended for regular or intermittent use for the acute treatment of pain associated with migraine and episodic cluster headache, as well as for the treatment of hemicrania continua and paroxysmal hemicrania.
- It also develops Truvaga 350, a personal use consumer electronics general wellness product and Truvaga Plus, an app-enabled general wellness product.
- It also offers non-invasive bioelectronic therapies for the treatment of chronic pain and wellness conditions.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PRPO | Precipio, Inc. | USD 23.32 | ▼ 0.72% |
| ATHE | Alterity Therapeutics Limited | USD 4.29 | ▲ 10% |
| TTOO | T2 Biosystems, Inc. | USD 0 | ▲ 0% |
| DARE | Dare Bioscience, Inc. | USD 1.92 | ▲ 2.13% |
| COCP | Cocrystal Pharma, Inc. | USD 1.02 | ▲ 6.25% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:04 UTC. This page is informational and not investment advice.